Allergy Therapeutics plc provided earnings guidance for the full year 2019. The Group now expects earnings for the full year 2019 to be ahead of market expectations. Net revenue is expected to be £73.7 million representing 8% annual growth on a reported and constant currency basis reflective of strong performance.